Plasticell is advancing multiple projects through which it will develop and manufacture red blood cell substitutes for human clinical transfusion and progress preclinical trials.
in-PharmaTechnologist presents a roundup of the latest drug delivery research, including bone marrow targeting nanoparticles and an imaging-treatment combo.
Mallinckrodt Pharmaceuticals has recalled one batch of its sodium chromate Cr-51 diagnostic agent after FDA post-marketing tests revealed that some of the products were “subpotent.”
In the future it may be possible to grow supplies of blood platelets in bioreactors rather than relying on donated supplies, according to US researchers.
Procter & Gamble (P&G) Pharmaceuticals has penned a deal
worth up to $511m (€375m) for a class of potential osteoporosis
drugs already well established as asthma therapies.
A new study has shown that certain human bone marrow stem cells can differentiate into sperm stem cells - potentially leading to a revolution in fertility therapy.
In the light of the death of former Russian security agent,
Alexander Litvinenko, pharma companies developing anti-radiation
drugs are increasingly under the spotlight.
Researchers at the University of Rochester and StemCapture have
unveiled a new device technology that makes it possible to harvest
stem cells from the blood, bypassing the controversial use of stem
cells sourced from embryos.
Israeli biopharma firm Kamada will manufacture transferrin for an
undisclosed European pharma firm embarking on the first ever
clinical trials of a drug that includes the substance.
According to a new report, worldwide revenues for cell and cytokine
therapies in regenerative medicine are set to reach $20.7 billion
(€17.3 billion) in 2010 in a sector that provides a viable
alternative to using drugs or other therapies.
A new drug candidate, which targets the protein that protects
cancer cells from dying, has been shown to exhibit increased
anti-tumour activity when combined with an existing cancer
treatments. The data gives hope to those who have...
Researchers in the US have developed a drug delivery technology
that directs therapeutics directly to bone, raising the possibility
of improved treatment for osteoporosis and other diseases affecting
bone, including cancer, reports...
Inhibitors of the enzyme histone deacetylase (HDAC) have entered
clinical testing in cancer, but may also prevent a serious and
life-threatening complication of bone marrow transplants.
